Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc.

Eli Lilly and Company (LLY) announced the successful completion of its acquisition of Verve Therapeutics. (VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for ...

Verve Therapeutics' most advanced new treatment candidate, VERVE-101, produced positive results in its first clinical trial. Inexperienced biotechnology investors were dealt a painful lesson, ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly and Company (NYSE: LLY ) and Verve Therapeutics, Inc. (NASDAQ: VERV ) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Shares of Verve Therapeutics (VERV 1.28%) sank as much as 30.7% this week, according to data from S&P Global Market Intelligence.The gene-editing company focused on the cardiovascular market ...

Verve Therapeutics (NASDAQ: VERV) is up 16.5% for the week. The biotech stock, which was as low as $41.52 a share on Monday, climbed as high as $48.39 by Thursday. For a relatively new stock (it ...

Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human p ...

Why Verve Therapeutics stock tanked. There were no issues on the safety front that clearly indicate trouble ahead for VERVE-101 but the initial portion of the study was less than flawless.